UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000058672
Receipt number R000066174
Scientific Title A Prospective Study on Early Detection of Cardiovascular Events via Remote Monitoring of Cheyne-Stokes Respiration
Date of disclosure of the study information 2025/08/02
Last modified on 2025/08/01 20:04:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Study for Early Automated Detection of Cardiovascular Events Using CPAP Remote Monitoring Data in Patients with OSA

Acronym

Early Anomaly Detection of Cardiovascular Events Using CPAP Data

Scientific Title

A Prospective Study on Early Detection of Cardiovascular Events via Remote Monitoring of Cheyne-Stokes Respiration

Scientific Title:Acronym

Abnormality Detection Using CSR Signals

Region

Japan


Condition

Condition

Sleep apnea

Classification by specialty

Medicine in general Cardiology Pneumology
Laboratory medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study continuously monitors the daily remote CPAP data of patients who have already been diagnosed with moderate to severe obstructive sleep apnea and are undergoing CPAP therapy. When a patient's data exceeds predefined thresholds, an anomaly alert is generated. The study aims to evaluate the effectiveness of this alert system for the early detection of actual cardiovascular events.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The study monitors three-day moving averages of parameters derived from remote CPAP monitoring data, such as the percentage of Cheyne-Stokes respiration. When predefined threshold criteria are exceeded, an anomaly alert is triggered. These alerts are then compared with the actual onset of cardiovascular events to evaluate the performance of the anomaly detection system.

Primary outcome measures include:
Accuracy,
Precision,
F measure.

Key secondary outcomes

The predefined threshold criteria will incorporate not only the absolute values of three-day moving averages (e.g., CSR%) but also the growth rate of these averages. Additional parameters such as air leakage and other relevant indicators will also be considered to identify optimal alert conditions.

Optimal cutoff values will be determined using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC). These methods will guide the selection of thresholds that maximize the accuracy of anomaly detection in relation to actual cardiovascular events.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

95 years-old >=

Gender

Male and Female

Key inclusion criteria

All patients currently undergoing treatment with the same CPAP device model at our institution.

Key exclusion criteria

Average CPAP usage rate less than 50%

Average CPAP usage time less than 4 hours

Target sample size

1300


Research contact person

Name of lead principal investigator

1st name Kimimasa
Middle name
Last name Saito

Organization

Medical Corporation MSC

Division name

Miesleep Clinic

Zip code

5190505

Address

446 sogo,obata,IseCity,Mie

TEL

0596290234

Email

k1saito@carrot.ocn.ne.jp


Public contact

Name of contact person

1st name Kimimasa
Middle name
Last name Saito

Organization

Medical Corporation MSC

Division name

Miesleep Clinic

Zip code

5190505

Address

446 Sogo, Obata-Chyo, Ise-shi, Mie

TEL

0596291159

Homepage URL


Email

k1saito@carrot.ocn.ne.jp


Sponsor or person

Institute

Miesleep Clinic

Institute

Department

Personal name

Kimimasa Saito


Funding Source

Organization

MieSleep Clinic

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation MSC

Address

446 Sogo, Obata-Chyo, Ise-shi, Mie 519-0502, Japan

Tel

0596291159

Email

ksaito.saito3@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW

δΈ‰ι‡ηœŒ


Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 08 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 08 Month 01 Day

Date of IRB

2025 Year 08 Month 01 Day

Anticipated trial start date

2025 Year 10 Month 01 Day

Last follow-up date

2026 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective validation using the optimized anomaly detection threshold will be conducted in approximately 1300 patients from October 2025 to September 2026. Time to event analysis will be performed using a Cox proportional hazards model to evaluate the predictive value of the detection for future cardiovascular events. Cumulative incidence of events will be visualized using Kaplan Meier survival curves.


Management information

Registered date

2025 Year 08 Month 01 Day

Last modified on

2025 Year 08 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066174